Gene therapy with poxvirus vectors

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 4, 2005, Pages 317-325

  Moroziewicz, Dorota ^a   Kaufman, Howard L ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Cancer gene therapy; Immunotherapy; Poxvirus; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; B7 ANTIGEN; CANCER VACCINE; CELL ADHESION MOLECULE; CHEMOKINE; COMPLEMENTARY DNA; CYTOKINE; DNA VACCINE; GANCICLOVIR; GENE PRODUCT; GLYCOPROTEIN GP 41; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOMODULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; NAKED DNA; PRIMER DNA; THYMIDINE KINASE; VIRUS VACCINE; VIRUS VECTOR;

ADAPTATION; ANTIBODY RESPONSE; CANARYPOX VIRUS; CLINICAL TRIAL; DNA VIRUS; FOWLPOX VIRUS; GENE EXPRESSION; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; POXVIRUS; POXVIRUS VECTOR; REVIEW; T LYMPHOCYTE; TRANSGENE; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS CHARACTERIZATION; VIRUS GENOME; VIRUS ISOLATION; VIRUS RECOMBINANT;

AIDS VACCINES; CANCER VACCINES; CLINICAL TRIALS; DNA, RECOMBINANT; GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; POXVIRIDAE;

DNA VIRUSES; MAMMALIA; POXVIRIDAE; VACCINIA VIRUS;

EID: 23344451837     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Ohlfest JR, Frandsen JL, Fritz S, Lobitz PD, Perkinson SG, Clark KJ, Nelsestuen G, Key NS, McIvor RS, Hackett PB, Largaespada DA: Phenotypic correction and long-term expression of Factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood (2005) 105(7):2691-2698.
2. Cotter FE: Antisense therapy for lymphomas. Hematol Oncol (1997) 15(1):3-11.
3. Robbins MA, Rossi JJ: Sensing the danger in RNA. Nat Med (2005) 11(3):250-251.
4. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, Endres S, Hartmann G: Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med (2005) 11(3):263-70.
5. van Dillen IJ, Mulder NH, Vaalburg W, de Vries EF, Hospers GA: Influence of the bystander effect on HSV-tk/GCV gene therapy. A review. Curr Gene Ther (2002) 2(3):307-322.
6. Milsom MD, Fairbairn LJ: Protection and selection for gene therapy in the hematopoietic system. J Gene Med (2004) 6(2):133-146.
7. Chen Y: Autoimmunity, immunologic tolerance, and gene therapy. Immunol Res (1998) 17(1-2):33-40.
8. Horig H, Kaufman HL: Local delivery of poxvirus vaccines for melanoma. Semin Cancer Biol (2003) 13(6):417-422.
9. Demeneix B, Hassani Z, Behr J-P: Towards multifunctional synthetic vectors. Curr Gene Ther (2004) 4(4):445-455.
10. Jooss K, Chirmule N: Immunity to adenovirus and adeno-associated viral vectors: Implications for gene therapy. Gene Ther (2003) 10(11):955-963.
11. Recombinant DNA Advisory Committee: Recombinant DNA and gene transfer. National Institutes of Health, Bethesda, MD, USA (2005). http://www4.od.nih.gov/oba/rac/aboutrdagt.htm
12. Traktman P: Poxviruses: An emerging portrait of biological strategy. Cell (1990) 62(4):621-626.
13. Moss B: Poxviridae: The viruses and their replication. In: Knipe DM, Howley PM (Eds). Fields Virology. 4th Edition, Lipincott Williams & Wilkins, Philadelphia, PA, USA (2001):2849-2883.
14. McFadden G: Poxvirus tropism. Nat Rev Microbiol (2005) 3(3):201-213.
15. Zaucha GM, Jahrling PB, Geisbert TW, Swearengen JR, Hensley L: The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Invest (2001) 81(12):1581-1600.
16. Smith GL, Vanderplasschen A, Law M: The formation and function of extracellular enveloped vaccinia virus. J Gen Virol (2002) 83(12):2915-2931.
17. Sodeik B, Krijnse-Locker J: Assembly of vaccinia virus revisited: De novo membrane synthesis or acquisition from the host? Trends Microbiol (2002) 10(1):15-24.
18. Senkevich TG, Ward BM, Moss B: Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene. J Virol (2004) 78(5):2357-2366.
19. Broyles SS: Vaccinia virus transcription. J Gen Virol (2003) 84(9):2293-2303.
20. Wollenberg A, Engler R: Smallpox, vaccination and adverse reactions to smallpox vaccine. Curr Opin Allergy Clin Immunol (2004) 4(4):271-275.
21. Bray M: Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res (2003) 58(2):101-114.
22. Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS, Snyder JT, Ahlers JD, Franchini G, Moss B, Berzofsky JA: Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci USA (2003) 100(16):9458-9463.
23. Panicali D, Paoletti E: Construction of poxviruses as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA (1982) 79(16):4927-4931.
24. Carroll MW, Moss B: Poxviruses as expression vectors. Curr Opin Biotechnol (1997) 8(5):573-577.
25. Moss B: Vaccinia and other poxvirus expression vectors. Curr Opin Biotechnol (1992) 3(5):518-522.
26. Mukherjee S, Haenel T, Himbeck R, Scott B, Ramshaw I, Lake RA, Harnett G, Phillips P, Morey S, Smith D, Davidson JA et al: Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation. Cancer Gene Ther (2000) 7(5):663-670.
27. Kalus RM, Kantor JA, Gritz L, Gomez Yafal A, Mazzara GP, Schlom J, Hodge JW: The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation. Vaccine (1999) 17(7-8):893-903.
28. Paoletti E: Applications of pox virus vectors to vaccination: An update. Proc Natl Acad Sci USA (1996) 93(21):11349-11353.
29. Broder CC, Earl PL: Recombinant vaccinia viruses. Design, generation, and isolation. Mol Biotechnol (1999) 13(3):223-245.
30. Domi A, Moss B: Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc Natl Acad Sci USA (2002) 99(19):12415-12420.
31. Paoletti E, Taylor J, Meignier B, Meric C, Tartaglia J: Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC. Dev Biol Stand (1995) 84:159-163.
32. Drexler I, Staib C, Sutter G: Modified vaccinia virus Ankara as antigen delivery system: How can we best use its potential? Curr Opin Biotechnol (2004) 15(6):506-512.
33. Staib C, Drexler I, Sutter G: Construction and isolation of recombinant MVA. Methods Mol Biol (2004) 269:77-100.
34. Johnston JB, McFadden G: Technical knockout: Understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes. Cell Microbiol (2004) 6(8):695-705.
35. Legrand FA, Verardi PH, Chan KS, Peng Y, Jones LA, Yilma TD: Vaccinia viruses with a serpin gene deletion and expressing IFN-γ induce potent immune responses without detectable replication in vivo. Proc Natl Acad Sci USA (2005) 102(8):2940-2945.
36. Alcami A: Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol (2003) 3(1):36-50.
37. Xiang Y, Condit RC, Vijaysri S, Jacobs B, Williams BR, Silverman RH: Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus. J Virol (2002) 76(10):5251-5259.
38. Hodge JW, Rad AN, Grosenbach DW, Sabzevari H, Yafal AG, Gritz L, Schlom J: Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J Natl Cancer Inst (2000) 92(15):1228-1239.
39. Zhu M, Terasawa H, Gulley J, Panicali D, Arlen P, Schlom J, Tsang KY: Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res (2001) 61(9):3725-3734.
40. Hodge JW, Grosenbach DW, Rad AN, Giuliano M, Sabzevari H, Schlom J: Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. Vaccine (2001) 19(25-26):3552-3567.
41. Tsang KY, Zhu M, Even J, Gulley J, Arlen P, Schlom J: The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells. Cancer Res (2001) 61(20):7568-7576.
42. Kaufman HL, Conkright W, Divito J Jr, Horig H, Kaleya R, Lee D, Mani S, Panicali D, Rajdev L, Ravikumar TS, Wise-Campbell S, Surhland MJ: A phase I trial of intralesional RV-B7.1 vaccine in the treatment of malignant melanoma. Hum Gene Ther (2000) 11(7):1065-1082.
43. Fleury B, Janvier G, Pialoux G, Buseyne F, Robertson MN, Tartaglia J, Paoletti E, Kieny MP, Excler JL, Riviere Y: Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with recombinant gp 160. J Infect Dis (1996) 174(4):734-738.
44. Evans TG, Keefer MC, Weinhold KJ, Wolff M, Montefiori D, Gorse GJ, Graham BS, McElrath MJ, Clements-Mann ML, Mulligan MJ, Fast P et al: A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes alone, or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis (1999) 180(2):290-298.
45. Cao H, Kaleebu P, Hom D, Flores J, Agrawal D, Jones N, Serwanga J, Okello M, Walker C, Sheppard H, El-Habib R et al: Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: Results of the HIV Network for Prevention Trials 007 vaccine study. J Infect Dis (2003) 187(6):887-895.
46. Hanke T, McMichael AJ, Mwau M, Wee EG, Ceberej I, Patel S, Sutton J, Tomlinson M, Samuel RV: Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine (2002) 20(15):1995-1998.
47. Renkvist N, Castelli C, Robbins PF, Parmiani G: A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother (2001) 50(1):3-15.
48. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, Restifo NP, Wunderlich JR, Seipp CA, Rogers-Freezer L, Morton KE et al: Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res (2003) 9(8):2973-2980.
49. Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J: Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst (1992) 84(14):1084-1091.
50. Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J: Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res (2003) 9(5):1837-1849.
51. McAneny D, Ryan CA, Beazley RM, Kaufman HL: Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol (1996) 3(5):495-500.
52. Marshall JL, Hawkins MJ, Tsang KY, Richmond E, Pedicano JE, Zhu MZ, Schlom J: Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol (1999) 17(1):332-337.
53. Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P, Tsang KY, Schlom J: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol (2000) 18(23):3964-3973.
54. Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY et al: A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res (2000) 6(5):1632-1638.
55. Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J: Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate (2002) 53(2):109-117.
56. Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, Whiteside TL, Schlom J, Wilding G, Weiner LM: Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 22(11):2122-2132.
57. Scholl SM, Balloul JM, Le Goc G, Bizouarne N, Schatz C, Kieny MP, von Mensdorff-Pouilly S, Vincent-Salomon A, Deneux L, Tartour E, Fridman W et al: Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother (2000) 23(5):570-580.
58. Zaloudik J, Li W, Jacob L, Kieny MP, Somasundaram R, Acres B, Song H, Zhang T, Li J, Herlyn D: Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice. Cancer Gene Ther (2002) 9(4):382-389.
59. Odin L, Favrot M, Poujol D, Michot JP, Moingeon P, Tartaglia J, Puisieux I: Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53. Cancer Gene Ther (2001) 8(2):87-98.
60. van der Burg SH, Menon AG, Redeker A, Bonnet MC, Drijfhout JW, Tollenaar RA, van de Velde CJ, Moingeon P, Kuppen PJ, Offringa R, Melief CJ: Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin Cancer Res (2002) 8(5):1019-1027.
61. Rosales C, Graham VV, Rosas GA, Merchant H, Rosales R: A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity. Cancer Immunol Immunother (2000) 49(7):347-360.
62. Valdez Graham V, Sutter G, Jose MV, Garcia-Carranca A, Erfle V, Moreno Mendoza N, Merchant H, Rosales R: Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus. Cancer (2000) 88(7):1650-1662.
63. Corona Gutierrez CM, Tinoco A, Lopez Contreras M, Navarro T, Calzado P, Vargas L, Reyes L, Posternak R, Rosales R: Clinical protocol. A phase II study: Efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus. Hum Gene Ther (2002) 13(9):1127-1140.
64. Qin H, Valentino J, Manna S, Tripathi PK, Bhattacharya-Chatterjee M, Foon KA, O'Malley BW Jr, Chatterjee SK: Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression. Mol Ther (2001) 4(6):551-558.
65. Chen B, Timiryasova TM, Gridley DS, Andres ML, Dutta-Roy R, Fodor I: Evaluation of cytokine toxicity induced by vaccinia virus-mediated IL-2 and IL-12 antitumour immunotherapy. Cytokine (2001) 15(6):305-314.
66. Kaufman HL, Flanagan K, Lee CS, Perretta DJ, Horig H: Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine (2002) 20(13-14):1862-1869.
67. Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW: Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res (2001) 61(1):206-214.
68. Yang AS, Monken CE, Lattime EC: Intratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen. Cancer Res (2003) 63(20):6956-6961.
69. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell (1992) 71(7):1093-1102.
70. Townsend SE, Allison JP: Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 259(5093):368-370.
71. Schwartz RH: Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell (1992) 71(7):1065-1068.
72. Carreno BM, Collins M: The B7 family of ligands and its receptors: New pathways for costimulation and inhibition of immune responses. Annu Rev Immunol (2002) 20:29-53.
73. Rad AN, Schlom J, Hodge JW: Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors. Crit Rev Oncol Hematol (2001) 39(1-2):43-57.
74. Aarts WM, Schlom J, Hodge JW: Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res (2002) 62(20):5770-5777.
75. Greiner JW, Zeytin H, Anver MR, Schlom J: Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res (2002) 62(23):6944-6951.
76. Horig H, Lee DS, Conkright W, Divito J, Hasson H, LaMare M, Rivera A, Park D, Tine J, Guito K, Tsang KW et al: Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother (2000) 49(9):504-514.
77. Kaufman HL, DeRaffele G, Divito J, Horig H, Lee D, Panicali D, Voulo M: A phase I trial of intralesional rV-TRICOM vaccine in the treatment of malignant melanoma. Hum Gene Ther (2001) 12(11):1459-1480.
78. Kaufman HL, Cheung K, Haskall Z, Horig H, Hesdorffer C, Panicali D, DeRaffele G, Spanknebel K: Clinical protocol. Intra-lesional rF-B7.1 versus rF-TRICOM vaccine in the treatment of metastatic cancer. Human Gene Ther (2003) 14(8):803-827.
79. Cayeux S, Beck C, Aicher A, Dorken B, Blankenstein T: Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur J Immunol (1995) 25(8):2325-2331.
80. Kaufman HL, DeRaffele G, Mitcham J, Moroziewicz D, Cohen SM, Hurst-Wicker KS, Cheung K, Lee DS, Divito J, Voulo M, Donovan J et al: Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest (2005): 115(7):1903-1912.
81. Flanagan K, Glover RT, Horig H, Yang W, Kaufman HL: Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response. Vaccine (2004) 22(21-22):2894-2903.
82. Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, McConkey SJ, Poulton I, Andrews L, Andersen RF, Bejon P et al: Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci USA (2005) 102(13):4836-41.